Oxazepam

• 产品号: DB00842
• CAS号: 604-75-1
• 分子式: C15H11ClN2O2
• 分子量: 286.71304

产品别名

• 标题: Oxazepam
• IUPAC标准名: 7-chloro-3-hydroxy-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
• IUPAC传统名: oxazepam
• 商标名: Aplakil; Praxiten; Limbial; Durazepam; Murelax; Lederpam; Astress; Azutranquil; Nesontil; Oxanid; Pacienx; Quilibrex; Seresta; Serpax; Sigacalm; Tazepam; Wy-3498 stic; Adumbran; Ansioxacepam; Anxiolit; Bonare; Drimuel; Droxacepam; Enidrel; Hi-Long; Isodin; Noctazepam; Notaral; Oxa-puren; QUEN; Rondar; Sedigoa; Serenal; Serenid; Serepax; Sobril; Tacepam; Uskan; Propax; Psiquiwas; Serax; Serenid-D; Vaben; Zaxopam
• 别名: Oxozepam; d-Oxazepam hemisuccinate; Oxazipam

产品登记号

• PubChem CID: 4616
• PubChem SID: 46506031
• CAS号: 604-75-1

产品性质

• 疏水性(logP): 2.8
• 溶解度: 179 mg/L

产品详细信息

详细说明 (English)

• Drug Groups: approved
• Description: Oxazepam is an intermediate-acting benzodiazepine used to treat alcohol withdrawal and anxiety disorders.
• Indication: For the treatment of anxiety disorders and alcohol withdrawal.
• Pharmacology: Oxazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.
• Toxicity: Symptoms of overdose include confusion, drowsiness, and lethargy.
• Affected Organisms: Humans and other mammals
• Biotransformation: No active metabolites. Metabolized via conjugation prior to elimination.
• Absorption: Well absorbed from the gastrointestinal tract following oral administration. Time to peak concentration = 2-4 hours. Onset of action is slow, > 3 hours, following oral administration.
• Half Life: 5-15 hours
• Protein Binding: 80-99%
• Elimination: This product has a single, major inactive metabolite in man, a glucuronide excreted in the urine.
• References: Peppers MP: Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996 Jan-Feb;16(1):49-57. [Pubmed] ; Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [Pubmed] ; Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [Pubmed] ; Christensen P, Lolk A, Gram LF, Kragh-Sorensen P: Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl). 1992;106(4):511-6. [Pubmed] ; Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. [Pubmed]
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com

参考文献

• Peppers MP: Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996 Jan-Feb;16(1):49-57. Pubmed
• Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. Pubmed
• Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. Pubmed
• Christensen P, Lolk A, Gram LF, Kragh-Sorensen P: Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl). 1992;106(4):511-6. Pubmed
• Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. Pubmed